WuXi AppTec boosts U.S. footprint with expanded New Jersey lab site

WuXi AppTec's ribbon cutting ceremony. (PRNewsfoto/WuXi AppTec)

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division (LTD) in New Jersey as it looks to boost its integrated testing service portfolio.

The big reveal this week, attended by State Senator Linda Greenstein, sees its existing site doubled, with total operation space swelling to more than 115,000 square feet and 200 jobs on the books.

After the expansion, LTD’s combined New Jersey operations will be “one of the largest labs for preclinical and clinical drug development testing in the United States,” the Shanghai-based company said in a statement.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The site is set up as a new “center of excellence” for drug development, strengthening the China company’s presence in the U.S. and expanding services to biopharma. WuXi says it will also “recruit extensively from the local talent base,” further boosting New Jersey’s life science credentials.

Dr. Jason Liu, SVP of WuXi AppTec and COO of the LTD, said: “The Garden State continues to be an important life science hub. This expansion will allow our team to deliver high quality service with faster turnaround times, better leverage the resources and expertise of the local pharmaceutical and biotechnology community, and develop a stronger connection with our customers.”

WuXi also has sites across several other U.S. states, as well as in its native China, Germany, Israel, South Korea and Japan.

Suggested Articles

Philips is cementing its commitment to becoming a healthcare technology provider, with plans to split off or sell its consumer appliances division.

Joe Jimenez has (another) new gig. The ex-Novartis boss joined the board of Century Therapeutics, a startup working on off-the-shelf cell therapies.

As Pfizer posts its full-year financials today, as usual it’s also sneaked in several dropped projects from its pipeline.